Theralase Technologies Inc.
Theralase Technologies Inc. (TLTFF) Financial Performance & Income Statement Overview
Review Theralase Technologies Inc. (TLTFF) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Theralase Technologies Inc. (TLTFF) Income Statement & Financial Overview
View the income breakdown for Theralase Technologies Inc. TLTFF across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $91190.00 | $410447.00 | $346583.00 | $100847.00 |
| Cost of Revenue | $77896.00 | $147269.00 | $145812.00 | $72884.00 |
| Gross Profit | $13294.00 | $263178.00 | $200771.00 | $27963.00 |
| Gross Profit Ratio | $0.15 | $0.64 | $0.58 | $0.28 |
| R&D Expenses | $877670.00 | $652975.00 | $650612.00 | $693707.00 |
| SG&A Expenses | $613102.00 | $526798.00 | $499612.00 | $474245.00 |
| Operating Expenses | $1.50M | $1.19M | $200771.00 | $27963.00 |
| Total Costs & Expenses | $1.58M | $1.34M | $1.30M | $1.24M |
| Interest Income | $18020.00 | $17870.00 | $17083.00 | $15157.00 |
| Interest Expense | $5002.00 | $5422.00 | $5834.00 | $6240.00 |
| Depreciation & Amortization | $65159.00 | $68583.00 | $68280.00 | $67185.00 |
| EBITDA | -$1.40M | -$844111.00 | -$863420.00 | -$1.06M |
| EBITDA Ratio | -$15.36 | -$2.06 | -$2.49 | -$10.51 |
| Operating Income | -$1.49M | -$925594.00 | $0.00 | -$1.14M |
| Operating Income Ratio | -$16.31 | -$2.26 | $0.00 | -$11.30 |
| Other Income/Expenses (Net) | $16343.00 | $7475.00 | $11919.00 | $6240.00 |
| Income Before Tax | -$1.47M | -$918119.00 | -$937534.00 | -$1.13M |
| Income Before Tax Ratio | -$16.13 | -$2.24 | -$2.71 | -$11.24 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$1.47M | -$918119.00 | -$937534.00 | -$1.13M |
| Net Income Ratio | -$16.13 | -$2.24 | -$2.71 | -$11.24 |
| EPS | -$0.006 | -$0.004 | -$0.004 | -$0.005 |
| Diluted EPS | -$0.006 | -$0.004 | -$0.004 | -$0.005 |
| Weighted Avg Shares Outstanding | $247.81M | $247.78M | $234.62M | $231.89M |
| Weighted Avg Shares Outstanding (Diluted) | $247.81M | $247.78M | $234.62M | $231.89M |
Over the past four quarters, Theralase Technologies Inc. demonstrated steady revenue growth, increasing from $100847.00 in Q2 2024 to $91190.00 in Q1 2025. Operating income reached -$1.49M in Q1 2025, maintaining a consistent -1631% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$1.40M, reflecting operational efficiency. Net income dropped to -$1.47M, with EPS at -$0.006. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan